Literature DB >> 26573004

Erratum to: miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer.

Helong Zhao1, Tasha Wilkie2, Yadwinder Deol3, Amita Sneh4, Akaansha Ganju5, Mustafa Basree6, Mohd W Nasser7, Ramesh K Ganju8.   

Abstract

Entities:  

Year:  2015        PMID: 26573004      PMCID: PMC4647705          DOI: 10.1186/s12943-015-0451-9

Source DB:  PubMed          Journal:  Mol Cancer        ISSN: 1476-4598            Impact factor:   27.401


× No keyword cloud information.
Erratum After publication of [1] it came to the authors’ attention that in the abstract. The sentence “In the present study, we show that S100A7 significantly downregulates the expression of miR-29b in Estrogen Receptor (ER)-positive breast cancer cells (represented by MCF7), and significantly upregulates miR-29b in ER-negative cells (represented by MDA-MB-231)”. Was Incorrect, the correct statement is “In the present study, we show that S100A7 significantly upregulates the expression of miR-29b in Estrogen Receptor (ER)-positive breast cancer cells (represented by MCF7), and significantly downregulates miR-29b in ER-negative cells (represented by MDA-MB-231)”.
  1 in total

1.  miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer.

Authors:  Helong Zhao; Tasha Wilkie; Yadwinder Deol; Amita Sneh; Akaansha Ganju; Mustafa Basree; Mohd W Nasser; Ramesh K Ganju
Journal:  Mol Cancer       Date:  2015-01-27       Impact factor: 27.401

  1 in total
  1 in total

1.  [Overpression of miR-29b suppresses the proliferation and induces apoptosis of cholangiocarcinoma cells].

Authors:  Kun Cao; Liangquan Sun; Yewei Zhang; Tengfei Wang; Haiyang Li; Shi Zuo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-09-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.